Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea
Phase 3
Terminated
- Conditions
- Diarrhea TravelersAntibiotic Resistant Infection
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 482
- Registration Number
- NCT03535272
- Locations
- 🇺🇸
Marina Rogova, New York, New York, United States
A Waiting Room-Delivered Video to Enhance Clinical Outcomes Among Persons Living With HIV
Not Applicable
Completed
- Conditions
- HIV Infections
- Interventions
- Other: Taking Care of Me Video
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 4003
- Registration Number
- NCT03508310
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
Phase 2
Recruiting
- Conditions
- Latent Tuberculosis
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 3400
- Registration Number
- NCT03474029
- Locations
- 🇦🇺
Liverpool Hospital, Sydney, Australia
🇺🇸George Washington University, Washington, District of Columbia, United States
🇺🇸New York City Bureau of TB Control, New York, New York, United States
HIV Prevention Among Latina Transgender Women Who Have Sex With Men: Evaluation of a Locally Developed Intervention
Not Applicable
Completed
- Conditions
- HIV Infections
- Interventions
- Behavioral: ChiCAS
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 144
- Registration Number
- NCT03465852
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Iron Status of Women and Young Children in the United States
Completed
- Conditions
- Iron-deficiencyNutritional Deficiency
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 5000
- Registration Number
- NCT03274726
An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment
Not Applicable
Completed
- Conditions
- TuberculosisDrug-resistant TuberculosisAdherence, MedicationAdherence, Patient
- Interventions
- Other: Electronic DOTOther: In-person DOT
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 216
- Registration Number
- NCT03266003
- Locations
- 🇺🇸
Fort Greene Chest Center, Brooklyn, New York, United States
🇺🇸Morrisania Chest Center, Bronx, New York, United States
🇺🇸Corona Chest Center, Jackson Heights, New York, United States
Duration of IPV Priming and Antibody Decay
Phase 4
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of ageBiological: Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of ageBiological: Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of ageBiological: Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of ageBiological: Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of ageBiological: Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 1645
- Registration Number
- NCT03202719
- Locations
- 🇧🇩
International Center for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
🇧🇩Mirpur clinic (International Center for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh
Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age
Phase 4
Completed
- Conditions
- Rubella Syndrome, CongenitalMeaslesRubella
- Interventions
- Biological: Measles-rubella (MR) vaccine at 9 monthsBiological: Measles-rubella (MR) vaccine at 6 and 9 months
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 620
- Registration Number
- NCT03071575
- Locations
- 🇧🇩
Icddr,B, Chāndpur, Bangladesh
JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo
Phase 3
Active, not recruiting
- Conditions
- Monkeypox Virus Infection
- Interventions
- Biological: JYNNEOS (Lyophilized Formulation)Biological: JYNNEOS (Liquid Formulation)
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 1600
- Registration Number
- NCT02977715
- Locations
- 🇨🇩
Tshuapa site, Boende, Tshuapa, Congo, The Democratic Republic of the
Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study
Phase 4
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: IPV at 14 and 22 weeks of age, RotaTeqBiological: IPV at 6 and fIPV at 22 weeks, RotarixBiological: IPV at 6 and fIPV at 22 weeks, RotaTeqBiological: IPV at 14 and 22 weeks of age, RotarixBiological: IPV at 14 and fIPV at 22 weeks, RotaTeqBiological: IPV at 14 and fIPV at 22 weeks, RotarixBiological: fIPV at 6-14-22 weeks of age, RotarixBiological: fIPV at 6-14-22 weeks of age, RotaTeq
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 1144
- Registration Number
- NCT02847026
- Locations
- 🇧🇩
International Center for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
© Copyright 2025. All Rights Reserved by MedPath